Shattuck Labs, Inc. (STTK) Research
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Market snapshot
- Symbol
- STTK
- Price
- $4.95
- Day change
- +4.43%
- Market cap
- $237.1M
- P/E ratio
- -11.14x
- 52-week range
- 0.712-8.33
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $12.75
Recent news
- Why Is Shattuck Labs Stock Trading Lower On Monday?
Shattuck Labs Inc. (NASDAQ:STTK) stock is down on Monday following news regarding its lead drug candidate, SL-325.
Peer companies
Recent insider activity
- Ashiya Mona — P-Purchase (1041667 shares) on 2026-06-11
- Ashiya Mona — P-Purchase (208333 shares) on 2026-06-11
- ORBIMED ADVISORS LLC — P-Purchase (1041667 shares) on 2026-06-11
- ORBIMED ADVISORS LLC — P-Purchase (208333 shares) on 2026-06-11
- SIEGALL CLAY B — P-Purchase (62500 shares) on 2026-06-09
Open Shattuck Labs, Inc. (STTK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.